New York Said to Probe Insurers Over Hepatitis C Drugs

Updated on
  • State attorney general probes limited access to treatments
  • Gilead, AbbVie drugs cost about $1,000 a pill before discounts

The New York state attorney general has asked 16 health insurance companies for information on their coverage of hepatitis C treatments, amid concerns that some companies are restricting coverage of the expensive medications, according to a person familiar with the investigation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.